



**Final Appraisal Recommendation**

Advice No: 0113 – February 2013

**Racecadotril (Hidrasec<sup>®</sup>▼) 10 mg and 30 mg granules  
for oral suspension**

**Submission by Lincoln Medical Ltd**

**Recommendation of AWMSG**

**Racecadotril (Hidrasec<sup>®</sup>▼) granules for oral suspension are not recommended for use within NHS Wales for the complementary symptomatic treatment of acute diarrhoea in infants (older than 3 months) and children.**

**AWMSG was not convinced that the case presented for clinical and cost effectiveness supported the use of this medicine in NHS Wales.**

**Additional note:**

- Patients who are currently being treated with racecadotril (Hidrasec<sup>®</sup>▼) granules for oral suspension for the indication stated above should have the option to continue their therapy until they and their clinicians consider it appropriate to stop.

In reaching the above recommendation AWMSG has taken account of the AWMSG Secretariat Assessment Report (ASAR), the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	Abbott Healthcare Products Ltd
Date of first issue	February 2013
Last reviewed	August 2016



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at [www.evidence.nhs.uk](http://www.evidence.nhs.uk).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 0113:  
raccadotril (Hidrased<sup>®</sup>) 10 mg and 30 mg granules for oral suspension. February 2013.

